

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM798674

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Partial Release of Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Wilmington Trust, National Association, as Agent		03/29/2023	National Banking Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Baudax Bio, Inc.		
Street Address:	490 Lapp Rd.		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Corporation: PENNSYLVANIA		
Name:	Baudax Bio N.A. LLC		
Street Address:	490 Lapp Rd.		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Limited Liability Company: DELAWARE		
Name:	Baudax Bio Limited		
Street Address:	490 Lapp Rd.		
City:	Malvern		
State/Country:	PENNSYLVANIA		
Postal Code:	19355		
Entity Type:	Private Limited Company: IRELAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	1339459		
Registration Number:	6080999	ANJESO (MELOXICAM) INJECTION	
CORRESPONDENCE DATA			
Fax Number:	2132897727		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			

OP \$65.00 1339459

Phone: 2134262623
Email: measonpriest@goodwinlaw.com
Correspondent Name: Michele Eason-Priest/Goodwin Procter LLP
Address Line 1: 601 S. Figueroa St.
Address Line 2: 41st Floor
Address Line 4: Los Angeles, CALIFORNIA 90017

ATTORNEY DOCKET NUMBER:	152763.371905
--------------------------------	---------------

NAME OF SUBMITTER:	Michele Eason-Priest
---------------------------	----------------------

SIGNATURE:	/Michele Eason-Priest/
-------------------	------------------------

DATE SIGNED:	03/29/2023
---------------------	------------

Total Attachments: 11

source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page1.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page2.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page3.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page4.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page5.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page6.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page7.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page8.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page9.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page10.tif
source=Baudax Bio_ Inc. - Partial Release (Wilmington IPSA) [Execution Version]#page11.tif

PARTIAL RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This PARTIAL RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “**Release**”) is made as of March 29, 2023 by Wilmington Trust, National Association (“**Secured Party**”), in its capacity as collateral agent (in such capacity, the “**Agent**”) for the benefit of itself and the financial institutions (the “**Lenders**”) from time to time party to the Credit Agreement (as defined below), in favor of Baudax Bio, Inc., a Pennsylvania corporation (the “**Borrower**”), together with Baudax Bio N.A. LLC, a Delaware limited liability company (the “**U.S. Guarantor**”), and Baudax Bio Limited, an Irish private company limited by shares having company number 562027 (the “**Irish Guarantor**” and, together with Borrower and U.S. Guarantor, each a “**Grantor**” and collectively the “**Grantors**”).

WHEREAS, in connection with that certain Credit Agreement, dated as of May 29, 2020, by and among the Borrower, the Agent and the Lenders (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), the Grantors entered into that certain Intellectual Property Security Agreement, dated as of May 29, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**IP Security Agreement**”), by the Grantors in favor of the Agent, pursuant to which the Grantors granted to the Agent, for the ratable benefit of the Lenders, a security interest in certain intellectual property of the Grantors;

WHEREAS, the IP Security Agreement was recorded with the Patent Division of the United States Patent and Trademark Office (“**USPTO**”) on June 10, 2020 at Reel 052891, Frame 0590, and with the Trademark Division of the USPTO on June 5, 2020 at Reel 006954, Frame 0776; and

WHEREAS, the Agent now desires to terminate and release its security interest in and to certain intellectual property collateral with respect to the Grantors.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

SECTION 1. Defined Terms. Unless otherwise specified herein, all capitalized terms used but not defined herein have the meanings given to them in the IP Security Agreement.

SECTION 2. Release of Grant of Security. Agent hereby terminates, releases and discharges to the Grantors all of the Agent’s security interest in all of the Grantors’ right, title and interest in and to, and reassigns to the Grantors any right, title and interest the Agent may have in or to, the following intellectual property collateral (the “**Released Collateral**”):

- (i) all patents and patent applications set forth in Schedule A hereto (the “**Patents**”);
- (ii) all trademark and service mark registrations and applications set forth in Schedule B hereto (including any United States intent-to-use trademark applications or intent-to-use service mark applications filed pursuant to Section 1(b) of the Lanham Act), together, in each case, with the goodwill symbolized thereby (the “**Trademarks**”);
- (iii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;
- (iv) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the

foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(v) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to or arising from any of the foregoing.

SECTION 3. Effect of Release. For the avoidance of any doubt, the release hereunder is limited only and solely to the Released Collateral, and shall not apply in any respect to any other Collateral (as such term is defined in the IP Security Agreement). The Agent reserves and retains its security interest (and any other right, title or interest) in and to all other such Collateral described therein, which security interest remains uninterrupted and undisturbed. Except as expressly modified by this Release, the IP Security Agreement remains and shall remain in full force and effect.

SECTION 4. Recordation. The Agent authorizes and requests that the Commissioner for Patents, the Commissioner for Trademarks and any other applicable government officer or relevant governmental authority record this Release.

SECTION 5. Governing Law. This Release shall be governed by, construed and enforced in accordance with the laws of the State of New York applicable to contracts made and performed in such state, without regard to principles of conflicts of law.

SECTION 6. Electronic Signatures. The parties to this Release consent to the execution by or on behalf of each other party of this Release, and the witnessing thereof, by electronic signature, provided that such manner of execution is permitted by law. The parties to this Release agree that an executed copy of this Release may be retained in electronic form and acknowledge that such electronic form shall constitute an original of this Release and may be relied upon as evidence of this Release.

[Signature page follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

**Wilmington Trust, National Association
as Agent**

By: 

Name: Andrew Lennon

Title: Assistant Vice President

Schedule A: Patents

Issued Patents

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
United States of America	10/357514	04-Feb-2003	2003-0185869	02-Oct-2003	7459283	02-Dec-2008	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	Baudax Bio, Inc.	Granted
United States of America	12/292091	12-Nov-2008	2009-0074875	19-Mar-2009	8323641	04-Dec-2012	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	Baudax Bio, Inc.	Granted
United States of America	10/784900	24-Feb-2004	2004-0229038	18-Nov-2004	8512727	20-Aug-2013	NANOPARTICULATE MELOXICAN FORMULATIONS	Baudax Bio, Inc.	Granted
European Patent Convention	04/785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAN FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
European Patent Convention	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
European Patent Convention	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Japan	2006-532300	27-Feb-2004	2007-505154	08-Mar-2007	4891774	22-Dec-2011	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
Japan	2010-233858	27-Feb-2004	2011-042670	03-Mar-2011	5548092	23-May-2014	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
United States of America	15/437534	21-Feb-2017	2017-0157061	08-Jun-2017	10471067	12-Nov-2019	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
United States of America	16/550239	25-Aug-2019	2019-0381062	19-Dec-2019	10709713	14-Jul-2020	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
United States of America	15/950367	11-Apr-2018	2018-0228809	16-Aug-2018	10463673	05-Nov-2019	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted
Canada	2517679	27-Feb-2004	2517679	13-Jan-2005	2517679	10-Apr-2012	NANOPARTICULATE MELOXICAN FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Belgium	04/785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAN FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
France	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAN	Baudax Bio, Inc.	Granted - To be abandoned
Germany	04785761.0	27-Feb-2004	1617816	25-Jan-2006	602004021107.9	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Hungary	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Ireland	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Italy	04785761.0	27-Feb-2004	1617816	25-Jan-2006	502009901749875	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Spain	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Switzerland	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAN FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
United Kingdom	04785761.0	27-Feb-2004	1617816	25-Jan-2006	1617816	13-May-2009	NANOPARTICULATE MELOXICAM FORMULATIONS	Baudax Bio, Inc.	Granted - To be abandoned
Austria	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Belgium	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Switzerland	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Germany	16161176.9	27-Feb-2004	3090731	09-Nov-2016	602004053216.9	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Denmark	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Spain	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
Finland	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
France	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
United Kingdom	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Hungary	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Hong Kong	19127168.3	27-Feb-2004	40003692	17-Apr-2020	40003692	28-May-2021	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Ireland	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Italy	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Netherlands	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Sweden	16161176.9	27-Feb-2004	3090731	09-Nov-2016	3090731	19-Sep-2018	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Hong Kong	17102503.7	27-Feb-2004	1228765	10-Nov-2017	1228765	11-Oct-2019	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Austria	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Switzerland	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
Germany	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Denmark	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Finland	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
United Kingdom	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Ireland	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Netherlands	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
Sweden	18186018.0	27-Feb-2004	3434261	30-Jan-2019	3434261	28-Oct-2020	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	Baudax Bio, Inc.	Granted - To be abandoned
United States of America	16/297020	08-Mar-2019	2019-0275053	12-Sep-2019	10881663	05-Jan-2021	METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	Baudax Bio, Inc.	Granted
United States of America	16/297095	08-Mar-2019	2019-0275054	12-Sep-2019	11458145	04-Oct-2022	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Granted

Patent Applications

Country	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Issue Date	Title	Owner Name	Status
European Patent Convention	19764737.3	08-Mar-2019	3761977	13-Jan-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
Japan	2020-571332	08-Mar-2019	2021-527697	14-Oct-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
China (People's Republic)	201980004945.1	08-Mar-2019	111201020	26-May-2020	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
Hong Kong	62020020480.3	08-Mar-2019	40032144	19-Mar-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
Korea, Republic of	10-2020-7027716	08-Mar-2019	10-2020-0130334	18-Nov-2020	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending
New Zealand	767981	08-Mar-2019	N/A	N/A	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
Australia	2019231858	08-Mar-2019	N/A	N/A	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	Baudax Bio, Inc.	Pending - To be abandoned
Hong Kong	62020021461.2	23-Oct-2019	40031604	12-Mar-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
China (People's Republic)	201980004887.2	23-Oct-2019	111356453	30-Jun-2020	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
Japan	2021-521960	23-Oct-2019	2022-505572	14-Jan-2022	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
Korea, Republic of	10-2021-7013779	23-Oct-2019	10-2021-0081354	01-Jul-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
Australia	2019364416	23-Oct-2019	N/A	N/A	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
New Zealand	775856	23-Oct-2019	N/A	N/A	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
Canada	3117209	23-Oct-2019	3117209	30-Apr-2020	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
European Patent Convention	19876037.3	23-Oct-2019	3870163	01-Sep-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending - To be abandoned
Russian Federation	202114360	23-Oct-2019	N/A	N/A	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
United States of America	17/287489	21-Apr-2021	2021-0386753	16-Dec-2021	N/A	N/A	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	Baudax Bio, Inc.	Pending
Australia	2019374827	07-Nov-2019	N/A	N/A	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
Canada	3118952	07-Nov-2019	3118952	14-May-2020	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
European Patent Convention	19881104.4	07-Nov-2019	3876910	15-Sep-2021	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
Japan	2021-524241	07-Nov-2019	2022-506696	17-Jan-2022	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending

<u>Country</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Publication No.</u>	<u>Publication Date</u>	<u>Patent No.</u>	<u>Issue Date</u>	<u>Title</u>	<u>Owner Name</u>	<u>Status</u>
Korea, Republic of	10-2021-7015337	07-Nov-2019	10-2021-0089175	15-Jul-2021	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
New Zealand	776380	07-Nov-2019	N/A	N/A	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
Russian Federation	2021116051	07-Nov-2019	N/A	N/A	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
United States of America	17/292403	07-May-2021	2022-0008430	13-Jan-2022	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending
China (People's Republic)	201980004883.4	07-Nov-2019	111565713	21-Aug-2020	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned
Hong Kong	62021024238.9	07-Nov-2019	40034393	23-Apr-2021	N/A	N/A	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	Baudax Bio, Inc.	Pending - To be abandoned

Schedule B: Trademarks

Trademark Registrations

TRADEMARK	CTRY	APP NO	APP DATE	REG NO	REG DATE
ANJESO	AR	3575482	23-Jan-17	2938976	30-May-18
ANJESO	WP	A0064395	20-Jan-17	1339459	20-Jan-17
ANJESO	AU	IR1339459	20-Jan-17	1838224	20-Jan-17
ANJESO	CN	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	CO	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	EM	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	GB	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	IN	IR1339459	20-Jan-17	3539489	20-Jan-17
ANJESO	JP	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	KR	IR1339459	20-Jan-17	1339459	20-Jan-17
ANJESO	NZ	IR1339459	20-Jan-17	1064583	20-Jan-17
ANJESO	BR	912207728	25-Jan-17	912207728	21-Aug-18
ANJESO	CA	1812536	5-Dec-16	TMA1053669	11-Sep-19
ANJESO	CL	1239210	23-Jan-17	1258001	29-Aug-17
ANJESO	MX	M1829526	7-Dec-16	1743197	17-Apr-17
ANJESO	PE	691152	23-Jan-17	251551	23-Jun-17
ANJESO	ZA	2017/02075	25-Jan-17	2017/02075	19-Nov-18
ANJESO	US	87/223688	2-Nov-16	1339459	20-July-21
ANJESO (stylized)	US	88/174417	30-Oct-18	6080999	20-Jun-16

Trademark Applications

None.¹

¹ The last two marks listed, US 87/223688 and 88/174417, both matured into issued trademarks after the IP SA was initially recorded with USPTO on 06/05/2020.